Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Following recent FDA-related challenges and cost-cutting initiatives, Sarepta has secured an extension on a large chunk of ...

Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

After Rocket Pharmaceuticals (RCKT) announced that the FDA has lifted the hold on RPA501 for Danon following alignment on a modified dosage and a ...

Sarepta and its gene therapy drug Elevidys were the target of 37 Freedom of Information Act requests during the first seven months of 2025, according to PoliScio Analytics’ competitive-intelligence ...